Researchers from Indian Institute of Science Education and Research (IISER) Mohali have discovered that unique antibodies ...

The single-dose dengue vaccine developed by Brazil’s Butantan Institute is 80.5% effective against hospitalization for the mosquito-borne disease for at least five years, per a phase 3 clinical trial ...

The Butantan-DV vaccine is tetravalent and offers protection against the four known serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Brazil has launched a pilot project to immunize 90 percent of the ...

Vietnam has launched clinical trials of a new antiviral drug that could offer fresh hope in the fight against dengue fever, a disease that still has no approved specific treatment worldwide.

Viruses are tiny agents that can infect a variety of living organisms, including bacteria, plants, and animals. Like other viruses, the dengue virus is a microscopic structure that can only replicate ...

Hoping to stem the global epidemic of Dengue, Panacea Biotec has begun final Phase III trials of its vaccine More than 10,000 volunteers across the country are enrolled in the study, overseen by the ...

Expert Rev Vaccines. 2013;12(9):995-1010. Based on the promising preclinical data, a monovalent recombinant DEN-80E protein has been tested in Phase I studies in flavivirus-naïve healthy volunteers.

Named "the world’s deadliest animal" by the CDC, mosquitoes kill more people than any other creature in the world. Mosquito-borne illnesses, including a rise in and the chikungunya virus and the ...

“Dengue can affect anyone living in or traveling to endemic areas - regardless of age, health and socio-economic circumstances,” said Gary Dubin, president of Takeda’s Vaccine Business Unit.

Vietnam has launched clinical trials of a new antiviral drug that could offer fresh hope in the fight against dengue fever, a disease that still has no approved specific treatment worldwide.